Natco Ltd

• 

  USFDA Observations on 2 Units Not to Impact Products: Natco

  Natco Pharma Ltd on Sunday said it has received "minor" observations by US Food & Drug Administration (USFDA) following recent inspections at its two facilities and they will not have an adverse impact on its current or future products.

• 

  India Agreed to Not Issue 'Compulsory' Drug Licences: US Industry Body

  The Indian government has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drug makers, a US business advocacy group said.

• Gilead's Hepatitis C Drug Patent Request Rejected

  India's patent office has rejected an application from US-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drug makers to launch cheaper generic versions of the $1,000-a-pill medicine.

• Natco Pharma's US Partner Files ANDA for Everolimus

  The drug which is used to prevent organ rejection after a kidney or liver transplant, generated sales of $43.5 million for the twelve-month period ending July 2014, based on industry sales data, Natco said.

• Glenmark Pharma Seeks Foreign Partners on Biological Drugs

  Glenmark Pharmaceuticals Ltd is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders, a senior executive said on Thursday.

• US Patents rejects Teva's plea on Copaxone; Natco shares up

  The United States Patent and Trademark Office (the "PTO") issued a final office action rejecting Teva's application seeking a reissue of US Patent No. 5,800,808 (the "'808 Patent"), which was found to be invalid by the Court of Appeals for the Federal Circuit in July 2013

• Delhi High Court bars export of Natco's generic cancer treatment drug

  The Delhi High Court has barred export of generic kidney and liver cancer medication Sorefenat manufactured by Natco Pharma Ltd on a plea of German drug major Bayer Corporation.

• Big Pharma pushes for US action against India over patent worries: report

  Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

• Novartis loses landmark India patent case on Glivec

  The Supreme Court dismissed Swiss drug-maker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

• Pharma giant Novartis waits nervously on Glivec drug patent verdict today

  Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country.

• BDR Pharma seeks license to sell version of a cancer drug

  BDR Pharmaceuticals International Pvt Ltd has applied to the patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, Dasatinib, through a so-called compulsory license mechanism, a BDR executive said on Monday.

• Lupin Ltd - Lupin in Alliance with Natco to commercialize generic equivalent of Tykerb Tablets

  Lupin Ltd has informed BSE regarding a Press Release dated June 23, 2011 titled "Lupin in Alliance with Natco to commercialize generic equivalent of Tykerb Tablets"

• Natco Pharma Ltd - Natco files ANDA for generic Tykerb, Ties up with Lupin Limited

  Natco Pharma Ltd has informed BSE regarding a Press Release dated June 23, 2011 titled "Natco files ANDA for generic Tykerb, Ties up with Lupin Limited".

• Natco Pharma Ltd - Press Release

  Natco Pharma Ltd has informed BSE that:  " K & C Pharmacy, a general partnership firm based out of New Jersey, USA (of which the Hyderabad based NATCO Pharma Limited is a 75% partner) has sold its right, title and interest in a retail pharmacy outlet known as Nicks' Drugs, based in Newark, New Jersey.  Nicks' Drugs revenue...

• Natco Pharma Ltd - Outcome of EGM

  Natco Pharma Ltd has informed BSE that the Extra Ordinary General Meeting (EGM) of the Company was held on December 15, 2010.